HMPL-306 (ranosidenib)
NCT07912398
Hutchmed · Phase 3 · Not yet recruiting · Enrollment 210
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| HMPL-306 250 mg QD | IDH-mutant grade 2 or 3 glioma (n = 210) | 250 mg | ITT | placebo | n/r |
No efficacy figure is in this file for this study.